<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01385176</url>
  </required_header>
  <id_info>
    <org_study_id>NECTAR-1109</org_study_id>
    <nct_id>NCT01385176</nct_id>
  </id_info>
  <brief_title>Neural Cardiac Therapy for Heart Failure Study (NECTAR-HF)</brief_title>
  <acronym>NECTAR-HF</acronym>
  <official_title>Neural Cardiac Therapy for Heart Failure Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve
      stimulation in heart failure patients with a New York Heart Association Class III, an
      ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than
      130 ms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to assess the impact of right vagal nerve stimulation on
      left ventricular remodeling, functional capacity, quality of life, and other measures in
      heart failure patients over a 6-month period. In addition, the study will assess the safety
      of the NECTAR-HF study system over an 18-month period.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular end-systolic dimension (LVESD)</measure>
    <time_frame>6-months post-implant</time_frame>
    <description>Echocardiography LVESD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>18-months post-implant</time_frame>
    <description>All-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular remodeling</measure>
    <time_frame>6-months post-implant</time_frame>
    <description>Echocardiography parameters of left ventricular structure and function (e.g., LVEF, LVESV and LVEDV, LVEDD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capacity</measure>
    <time_frame>6-months post-implant</time_frame>
    <description>Assessment of functional capacity (e.g., peak VO2, anaerobic threshold)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6-months post-implant</time_frame>
    <description>Assessments of patient reported quality of life (i.e., MLWHFQ and SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure status</measure>
    <time_frame>6-months post-implant</time_frame>
    <description>Assessment of heart failure status (i.e., NYHA Class)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Heart Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group will be implanted with study system, but will receive no therapy until 6-month cross-over.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vagal Nerve Stimulation</intervention_name>
    <description>Patients randomized to therapy arm with receive right vagal nerve stimulation. Patients randomized to control arm will not receive right vagal nerve stimulation for the first 6-months post-implant, after which they will also receive therapy.</description>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or above, and of legal age to give informed consent specific to national laws

          -  Willing and capable of providing informed consent

          -  Capable of participating in all testing associated with this clinical investigation

          -  Stable symptomatic heart failure NYHA class II-III

          -  Left ventricular (LV) ejection fraction equal or smaller than 35 %

          -  Left ventricular end diastolic diameter (LVEDD) of 5.5 cm or greater

          -  Prescribed to optimal pharmacologic therapy

        Exclusion Criteria:

          -  QRS larger than 130 ms

          -  Patients who have been hospitalized for heart failure and who required the use of HF
             IV therapy within 30 days before enrollment

          -  Patients unable to tolerate anesthesia required for implant

          -  Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass
             graft, cerebral vascular accident, or transient ischemic attack within previous 90
             days before enrollment

          -  Patients whose primary cause of heart failure is mitral or aortic valve disease, with
             a severe classification

          -  Patients with persistent or permanent atrial fibrillation within 90 days prior to
             enrollment

          -  Pacemaker indicated patients

          -  Patients whose heart failure is due to congenital heart disease

          -  Patients who have started treatment for sleep apnea or sleep disordered breathing with
             therapies to maintain airway patency (e.g., CPAP, Bi-PAP,APAP) with or without oxygen
             supplementation within the previous 6 months prior to enrollment

          -  Patients with hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy
             (e.g. amyloidosis, sarcoidosis)

          -  Patients with documented chronic obstructive lung disease

          -  Patients on or indicated for renal dialysis

          -  Type 1 diabetic patients

          -  Type 2 diabetic patients that have been treated with insulin for more than 5 years
             prior to enrollment

          -  Patients with a life expectancy of less than 12 months per physician judgment

          -  Patients involved in any concurrent clinical investigation

          -  Women of childbearing potential who are or might be pregnant at the time of the study
             or breastfeeding

          -  Patients with a prior cardiac transplant or expecting a heart transplant operation
             within the next 12 months

          -  Patients with a prior vagotomy

          -  Patients with prior or existing vagal nerve stimulation treatment

          -  Patients implanted with any active implantable medical device other than a left sided
             single or dual chamber implantable cardioverter defibrillator (ICD) with bipolar
             sensing, or a left sided CRT device with each sensing channel programmed to either
             bipolar sensing or no sensing. All CRT patients must have had CRT for at least 1 year
             prior to enrollment. The total number of CRT patients will not exceed 30

          -  Patients with locally implanted semi-/permanent devices such as vascular catheters,
             etc. that would interfere with the NECTAR-HF study system

          -  Patients with previously implanted devices on the right side that became infected
             before removal

          -  Patients with previous neck surgery and resultant scar formation that interferes with
             the ability to implant the study system on the right side of the neck
             (Thyroid/parathyroid, carotid artery etc)

          -  Patients with known recurrent nerve paralysis

          -  Patients who have undergone radiotherapy for thyroid disease/cancer

          -  Patients who have existing or prior tracheotomy

          -  Patients with severe vertebral cervical disease and limited mobility in the neck;
             includes those that frequently wear a brace

          -  Patients with carotid murmur/vascular bruit/carotid artery lesion

          -  Patients with known/suspected vascular malformation in carotid/vertebral circulatory
             bed

          -  Patients who are likely to need an MRI of the neck area because of previous medical
             conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faiez Zannad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation Clinique (CIC), Batiment Louis Mathieu, CHU de Nancy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL Bruxelles</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Pierre Drouin, CHU de Nancy</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Nancy</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Cardiologique</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <state>Brandenburg</state>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum GmbH, Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Niguarda Cà Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. O. Dei Colli - Monaldi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madird</city>
        <state>Madrid</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra, Avenida Pio XII s/n</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol, NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital, NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L14 3PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital, University College London Hospitals, NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1G 8PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>De Ferrari GM, Tuinenburg AE, Ruble S, Brugada J, Klein H, Butter C, Wright DJ, Schubert B, Solomon S, Meyer S, Stein K, Ramuzat A, Zannad F. Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. Eur J Heart Fail. 2014 Jun;16(6):692-9. doi: 10.1002/ejhf.80. Epub 2014 May 20.</citation>
    <PMID>24846173</PMID>
  </reference>
  <results_reference>
    <citation>Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, Ramuzat A, Schubert B, Daum D, Neuzil P, Botman C, Castel MA, D'Onofrio A, Solomon SD, Wold N, Ruble SB. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2015 Feb 14;36(7):425-33. doi: 10.1093/eurheartj/ehu345. Epub 2014 Aug 31.</citation>
    <PMID>25176942</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2011</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Congestive heart failure</keyword>
  <keyword>New York Heart Association Class II-III</keyword>
  <keyword>Vagal therapy</keyword>
  <keyword>Vagal nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 17, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>March 23, 2017</submitted>
    <returned>May 2, 2017</returned>
    <submitted>June 13, 2017</submitted>
    <returned>January 8, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

